Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Inscripta

Inscripta
2015 FOUNDED
PRIVATE STATUS
101-200 EMPLOYEES
Series D LATEST DEAL TYPE
$125M LATEST DEAL AMOUNT
10 INVESTORS
Description

Operator of a gene editing technology company intended to offer researchers with necessary tools for cutting-edge, single cell engineering. The company's genome engineering technology generates low-cost libraries of thousands of designer protein, pathway or genome variants each with specifically defined and trackable mutations, enabling researchers to determine impact of specific changes through rapid selection and high throughput screening allowing research timelines and costs to be reduced.

Formerly Known As
Muse Biotechnology, Inc.
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • 5500 Central Avenue
  • Suite 220
  • Boulder, CO 80301
  • United States

+1 (720) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Inscripta’s full profile, request a free trial.

Inscripta Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series D) 10-Dec-2019 $125M 00000 00000 Completed Generating Revenue
4. Later Stage VC (Series C1) 29-Mar-2019 0000 00000 00000 Completed Generating Revenue
3. Later Stage VC (Series C) 28-Feb-2019 000.00 000.00 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 16-Feb-2017 $23M $29M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 10-May-2016 $6.04M $6.04M 000.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Inscripta Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series D 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series C-1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series C 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 19,784,629 $0.000010 6% $1.17 $1.17 1x $1.17 17.56%
Series A 5,157,970 $0.000010 6% $1.17 $1.17 1x $1.17 4.58%
To view this company’s complete Cap Table, request access »

Inscripta Competitors (15)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Synthego Venture Capital-Backed Redwood City, CA 000 00000 00000000000 00000
0000 00000000 Venture Capital-Backed Toronto, Canada 00 0000 00000000000 0000
0000000 Venture Capital-Backed Beijing, China 000.00 0000000000 0 000.00
0000000 Corporation Seoul, South Korea 00
000000000 00000000 Venture Capital-Backed La Jolla, CA 000 00000 00000000000 00000
To view this company’s complete list of competitors, request access »

Inscripta Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 00000000000 05-Sep-2018 000000000000000000 Biotechnology 00000 0000 00.0
To view this company’s complete investment and acquisition history, request access »

Inscripta Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
JS Capital Management Asset Manager Minority 000 0000 000000 0
Oak HC/FT Venture Capital Minority 000 0000 000000 0
Spruceview Capital Partners Hedge Fund Minority 000 0000 000000 0
iGlobe Partners Venture Capital Minority 000 0000 000000 0
Mérieux Développement Growth/Expansion Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Inscripta Executive Team (12)

Name Title Board
Seat
Contact
Info
Kevin Ness Ph.D Chief Executive Officer & Board Member
Ron Mcgrath Chief Financial Officer
Michael Graige Ph.D Chief Technical Officer
Andrew Garst Ph.D Co-Founder & Principal Scientist
Jason Gammack Chief Commercial Officer

4 Former Executives

You’re viewing 5 of 12 executives. Get the full list »

Inscripta Board Members (6)

Name Representing Role Since Contact
Info
Bryan Roberts Ph.D Venrock Board Member 000 0000
Eric Moessinger ND Capital Board Observer 000 0000
John Stuelpnagel Self Chairman 000 0000
Kevin Ness Ph.D Inscripta Chief Executive Officer & Board Member 000 0000
Roger Wyse Ph.D Spruce Capital Partners Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 6 board members. Get the full list »